RESEARCH TRIANGLE PARK, N.C. — March 3, 2026 — Leads & Copy — Opus Genetics, Inc. (Nasdaq: IRD) will present at several upcoming investor conferences, the company announced today.
The clinical-stage biopharmaceutical company, which focuses on developing gene therapies for inherited retinal diseases (IRDs), will participate in the Leerink Global Healthcare Conference on March 10 at 3:00 p.m. ET in Miami, FL.
Opus Genetics will also present at the Citizens Life Sciences Conference on March 11 at 2:50 p.m. ET, also in Miami, FL.
The company’s management team is scheduled to present at the RBC Capital Markets Global Ophthalmology Conference on March 25 at 11:45 a.m. ET. This conference will be held virtually.
Webcasts of the conference presentations will be available on Opus Genetics’ website under the Investors section: Events.
Opus Genetics is developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The company’s pipeline includes seven AAV-based programs, including OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery.
The Company is based in Research Triangle Park, NC.
Source: Opus Genetics, Inc.
